Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Govt to Deliver 4.12 Million Comirnaty Doses for COVID-19 Boosters: Minister
The Japanese government will deliver a total of 4.12 million doses of Pfizer’s COVID-19 vaccine Comirnaty to prefectural authorities for use as a booster that will be given to a yet-to-be determined scope of people eight months after their second…
To read the full story
Related Article
- Japan Approves Pfizer COVID-19 Vaccine for Booster Use
November 11, 2021
- Pfizer’s COVID-19 Booster Now in Line for Approval for Age 18-Plus
November 11, 2021
- Pfizer’s COVID-19 Booster Up for PAFSC Review on Nov. 10
November 5, 2021
REGULATORY
- Public Comments Warn Japan’s Drug Pricing System Cannot Reflect Inflation: Chuikyo
February 2, 2026
- Chuikyo Agrees to Apply Originator Optimal-Use Guidelines to Biosimilars
February 2, 2026
- MHLW Panel Sets Safety Rules for Upcoming Pomalyst Generics
February 2, 2026
- Japan Panel Green-Lights Pfizer’s Tukysa, Wider Labels for Tezspire, and More Drugs
January 30, 2026
- MHLW to Ease Uniform Driving Restrictions on Oral Antiepileptics
January 29, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…